MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Vivani Medical

Fermé

1.01 1

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.98

Max

1.01

Chiffres clés

By Trading Economics

Employés

36

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+292.16% upside

Dividendes

By Dow Jones

Prochains Résultats

9 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

61M

Ouverture précédente

0.01

Clôture précédente

1.01

Vivani Medical Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 juin 2024, 15:28 UTC

Principaux Mouvements du Marché

Vivani Medical Shares Up, FDA Cleared New Drug Application to Start Diabetes Trial

Comparaison

Variation de prix

Vivani Medical prévision

Objectif de Prix

By TipRanks

292.16% hausse

Prévisions sur 12 Mois

Moyen 4 USD  292.16%

Haut 4 USD

Bas 4 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Éléments financiers

$

À Propos Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.